Autoimmunity Program
Autoimmune Disease
PreclinicalActive
Key Facts
About Accipiter Biosciences
Accipiter Biosciences is a private, preclinical-stage biotech leveraging computational protein design to create novel, multifunctional agonist biologics. Founded in 2018 by alumni of the University of Washington's Institute for Protein Design, the company has raised $12.7 million in seed funding from a syndicate co-led by Takeda and Flying Fish Partners. Accipiter is advancing its internal pipeline in autoimmunity and oncology while also engaging in strategic partnerships with major pharmaceutical companies like Pfizer and Kite Pharma to expand its platform capabilities.
View full company profileTherapeutic Areas
Other Autoimmune Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Fusion Immunotherapeutic | HCW Biologics | Clinical Trial |
| Autoimmune Disease Program | Carisma Therapeutics | Discovery |
| Not Specified (Autoimmune Focus) | Narwhal Bio | Pre-clinical |
| Undisclosed Precision Biologic | Rhapsogen | Pre-clinical |
| First-in-class autoimmune disorder target | Genesis Therapeutics | Pre-clinical |
| GIM-407 | Georgiamune | Preclinical |
| Undisclosed Autoimmune Program | TianTi Biotherapeutics | Preclinical |
| Undisclosed Transcription Factor | Talus Bioscience | Discovery |
| Appus | BioVectis | Pre-clinical |
| Leap 1121 | Ability Biotherapeutics | Preclinical |
| ALLO-329 | Allogene Therapeutics | Phase 1 |